Inclusion Criteria:

          1. Male or female patients, age ≥ 18 years

          2. Documented definitive diagnosis at screening of AML, B-ALL or BPDCN (according to
             standard of care testing) and CD123 positivity of more than 20 % of blasts.

               -  Relapsed or refractory AML,

               -  Relapsed or refractory B-ALL (in patients aged over 25 years or over 18 years
                  without access to an approved chimeric antigen receptor (CAR)-T cell product at
                  time point of potential inclusion into this study),

               -  Patients with histological and/or cytological evidence of BPDCN in the peripheral
                  blood, bone marrow (BM), spleen, lymph nodes, skin, and/or other sites that is
                  persistent/recurrent following prior standard of care treatment for BPDCN

          3. Eastern Cooperative Oncology Group (ECOG) of 0 to 1

          4. Life expectancy of at least 2 months

          5. Adequate renal and hepatic laboratory assessments:

          6. Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF) of ≥ 45 % as
             assessed by transthoracic two-dimensional echocardiography

          7. Permanent venous access existing (e.g. port-system) resp. acceptance of implantation
             of a device

          8. Able to give written informed consent

          9. Weight ≥ 45 kg

         10. Negative pregnancy; routinely using a highly effective method of birth control

        Exclusion Criteria:

          1. Acute promyelocytic leukemia (t15;17) and T-ALL

          2. Manifestation of AML, ALL or BPDCN in central nervous system

          3. Bone marrow failure syndromes

          4. Cardiac disease: i.e. heart failure (NYHA III or IV); unstable coronary artery
             disease, myocardial infarction or serious cardiac ventricular arrhythmias requiring
             anti-arrhythmic therapy within the last 6 months prior to study entry

          5. Patients undergoing renal dialysis

          6. Pulmonary disease with clinical relevant hypoxia

          7. Parkinson, epilepsy and, stroke or presence or history of seizures, paresis, aphasia
             or intracranial hemorrhage

          8. History or presence of disseminated intravascular coagulation (DIC) or thromboembolism

          9. Hemolytic anemia

         10. Multiple sclerosis

         11. Active infectious disease considered by investigator to be incompatible with protocol
             or being contraindications for lymphodepletion therapy

         12. Presence of urotoxicity from previous chemo- or radiotherapy or urinary outflow
             obstruction

         13. Allogeneic stem cell transplantation within last two months or Graft versus host
             disease (GvHD) requiring immunosuppressive therapy

         14. Vaccination with live viruses less than 2 weeks prior lymphodepletion therapy

         15. Major surgery within 28 days

         16. Other malignancy requiring active therapy but adjuvant endocrine therapy is allowed

         17. Treatment with any investigational drug substance or experimental therapy within 4
             weeks or 5 half-lives (whatever is shorter) of the substance prior to the day of
             apheresis

         18. Prior treatment with gene therapy products

         19. Use of checkpoint inhibitors within 5 half-lives of the respective substance

         20. Autoimmune diseases requiring systemic steroids or other systemic immunosuppressants

         21. Pregnant or breastfeeding women

         22. Psychologic disorders, drug and/or significant active alcohol abuse

         23. Known history of human immunodeficiency virus (HIV) or active/chronic infection with
             hepatitis C virus (HCV) or hepatitis B virus (HBV)

         24. Presence of autoantibodies against La/Sjögren syndrome (SS)-B or presence or history
             of autoimmune diseases

         25. Known hypersensitivity to cellular component (UniCAR02-T) and/or targeting module
             (TM123) excipients or to compounds of the lymphodepletion therapy or tocilizumab or
             corticosteroids

         26. Evidence suggesting that the patient is not likely to follow the study protocol

         27. Incapability of understanding purpose and possible consequences of the trial

         28. Patients who should not be included according to the opinion of the investigator